Change to Part B pay draws specialty ire February 01, 2018By Bob GattySeveral medical societies, including the AUA and the American Society of Clinical Oncology, are urging congressional leaders to prevent CMS from applying MIPS adjustments to Part B drug payments.
In this issue
2017 tax law: Here are the changes you can expectHere is a brief overview of the Tax Cuts and Jobs Act passed by Congress. Newer agent efficacious in non-metastatic castration-resistant PCa February 06, 2018By John SchieszerAdding apalutamide prior to metastases may benefit men with prostate cancer who are no longer responding to androgen deprivation therapy, according to new phase III study findings.
Chemo improves QoL in men with non-metastatic, metastatic PCa February 06, 2018By John SchieszerDocetaxel (Taxotere) appears to help improve overall quality of life and delay time for subsequent therapy in men with both non-metastatic and metastatic prostate cancer, according to a new analysis of STAMPEDE trial results.
PCa-specific mortality not affected by comorbidity February 01, 2018By Bryant FurlowComorbidity does not affect prostate cancer-specific mortality, according to authors of a large prospective observational study of men in Sweden, published in the Journal of Clinical Oncology (2017; 35:3566-74).
Study: Monopolar TURP utilization on the decline February 01, 2018By Aine CrytsAlthough monopolar transurethral resection of the prostate remains the standard of care for bladder outlet obstruction secondary to BPH, its utilization has decreased in recent years, according to a recent study. [Quiz]: Abnormality seen in post-PCNL imaging February 09, 2018By Igor Sorokin MDA 42-year-old female undergoes right percutaneous nephrolithotomy (PCNL) for a complete staghorn calculus. As a routine after PCNL, a chest-x-ray was obtained using fluoroscopy. What abnormality is seen?
ADT+EBRT improves OS in men with post-RP LN metastases February 01, 2018By Badar M. Mian MD"While improving local control seems to be important, especially in those with high-risk features, it’s not clear whether adjuvant EBRT is necessarily better than early salvage EBRT," writes Badar M. Mian, MD.